
Opinion|Videos|August 13, 2024
Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data
Experts give an overview of the ASCO 2024 data.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
The phase 2
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
FDA clears Revi Extend implant for urgency urinary incontinence
4
CAPItello-281 Trial Design and Efficacy Data in mHSPC
5













